Literature DB >> 10587280

Psychological strategies for discontinuing benzodiazepine treatment.

D A Spiegel1.   

Abstract

Successful discontinuation of therapeutic drugs requires patients to negotiate two potentially difficult phases. First, they must complete the drug discontinuation procedure itself, which may entail coping with rebound and withdrawal symptoms as well as anxiety due to stopping a treatment on which they depend psychologically. Second, they must maintain drug abstinence over time, despite possible exacerbations or recurrences of the disorder that the drug was treating. For optimal success, interventions aimed at assisting patients to discontinue drug use must address both of those tasks. Patients' ability to discontinue benzodiazepines seems to be strongly influenced by cognitive appraisals of the threat represented by symptoms and of their own competence to cope with it without medication. For problems of that kind, cognitive and behavioral techniques such as those developed for the treatment of panic disorder may be especially well-suited. Currently, the most successful approaches to benzodiazepine discontinuation include the following components: (1) assisting with initial drug discontinuation, educating patients about benzodiazepine dependence and withdrawal, and about the kinds of symptoms that can emerge as the drug dose is decreased, combined with a flexible drug taper conducted in supportive collaboration with the patient; and (2) dealing with exacerbations of the illness, and providing disorder-specific cognitive-behavioral treatment as an alternative to the resumption of pharmacotherapy. It seems to be crucial that the drug taper be completed before psychological treatment concludes.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10587280     DOI: 10.1097/00004714-199912002-00004

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  9 in total

1.  Psychotropic drug use among older people in general practice: discrepancies between opinion and practice.

Authors:  Andrea Lasserre; Nadia Younès; Thierry Blanchon; Inge Cantegreil-Kallen; Christine Passerieux; Guy Thomas; Christine Chan-Chee; Thomas Hanslik
Journal:  Br J Gen Pract       Date:  2010-04       Impact factor: 5.386

Review 2.  The Black Book of Psychotropic Dosing and Monitoring.

Authors:  Alan F Schatzberg; DeBattista Charles
Journal:  Psychopharmacol Bull       Date:  2018-01-15

3.  Withdrawal from long-term benzodiazepine use: randomised trial in family practice.

Authors:  Catalina Vicens; Francisca Fiol; Joan Llobera; Francisco Campoamor; Catalina Mateu; Santiago Alegret; Isabel Socías
Journal:  Br J Gen Pract       Date:  2006-12       Impact factor: 5.386

Review 4.  Withdrawing Benzodiazepines in Patients With Anxiety Disorders.

Authors:  Malcolm Lader; Andri Kyriacou
Journal:  Curr Psychiatry Rep       Date:  2016-01       Impact factor: 5.285

5.  Older primary care patients' willingness to consider discontinuation of chronic benzodiazepines.

Authors:  Joan M Cook; Tatyana Biyanova; Richard Thompson; James C Coyne
Journal:  Gen Hosp Psychiatry       Date:  2007 Sep-Oct       Impact factor: 3.238

Review 6.  Withdrawing benzodiazepines in primary care.

Authors:  Malcolm Lader; Andre Tylee; John Donoghue
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

7.  Medication dependence and anxiety.

Authors:  Lisa L von Moltke; David J Greenblatt
Journal:  Dialogues Clin Neurosci       Date:  2003-09       Impact factor: 5.986

Review 8.  Deprescribing benzodiazepines and Z-drugs in community-dwelling adults: a scoping review.

Authors:  André S Pollmann; Andrea L Murphy; Joel C Bergman; David M Gardner
Journal:  BMC Pharmacol Toxicol       Date:  2015-07-04       Impact factor: 2.483

Review 9.  Treatment of anxiety disorders.

Authors:  Borwin Bandelow; Sophie Michaelis; Dirk Wedekind
Journal:  Dialogues Clin Neurosci       Date:  2017-06       Impact factor: 5.986

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.